Vyzer Weekly

Vyzer Weekly is a recurring live conversation where investors come together to think more clearly about markets, risk, and private investing. Each Thursday we break down what actually mattered in the markets, take a focused deep dive into a key investing principle, and open the floor for real discussion.No hype, no pitches, no predictions, just practical clarity and a smarter way to approach investing.Join these shows live: https://go.vyzer.co/vyzerweeklycalls

Vyzer Weekly is a business podcast hosted by Vyzer, with 23 episodes on record and a Required Pod Score of 80.

Vyzer hosts Vyzer Weekly, a business show with 23 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #26

  What Investors Get Wrong About Biotech

  Sep 24, 202651 minS1

  Most LPs in this community underwrite things they can see. A rent roll, a cap rate, a debt schedule, a comp set two streets over. Biotech offers none of that. It asks you to fund a molecule that either works or does not, on a timeline you do not control, with no distributions along the way. So most passive investors skip the category entirely and call it a science problem. The argument on this call is that it was never a science problem. By 2030, somewhere around $250 to $300 billion a year of branded drug revenue goes generic, the biggest patent cliff on record. Big pharma cannot invent its way out of that hole fast enough, and the math on why is stark: the real cost of an approved drug, done honestly, is $7 to $9 billion, not the $1 billion everyone quotes. That is not a forecast. It is a structural buyer with a deadline. Litan Yahav and Mike Arndorfer are joined by Ran Nussbaum, co-founder and managing partner of Pontifax, who has been investing in life sciences since 2004 and sat on the boards of Kite Pharma, Prevail, cCAM and ArQule before each was acquired. In this conversation, we discuss: Why "I don't understand the science" is the wrong reason to skip the category The patent cliff in plain numbers, and what a forced buyer with a deadline does to price The real $7-9B cost of an approved drug, and why that forces big pharma to buy instead of build How a CAR-T therapy went from unproven idea to an 85%+ complete response rate and an acquisition The ultra-orphan playbook: proving a drug in 60 patients worldwide to unlock a much bigger population later Where AI actually helps in drug development today, and where it still doesn't Why biotech returns don't move with rates, occupancy, or cap rates The honest cost of entry: eight to twelve year holds, a deep J-curve, zero cash flow while you wait Why some of the best-looking phase 2 results in an entire field don't survive phase 3 This is not a presentation or a pitch. It's a live, open conversation focused on how passive investors can think clearly about an asset class most of them have written off without looking at it. About Ran Nussbaum Ran is co-founder and managing partner of Pontifax, a healthcare-dedicated investment firm he started in 2004, with offices in Tel Aviv and Boston. He has served on the boards of Kite Pharma (acquired by Gilead), Prevail (Lilly), cCAM Therapeutics (Merck) and ArQule (Merck). Listen and subscribe YouTube: https://www.youtube.com/playlist?list=PLVH9Pz5-HyDBtJSrgG6tbZhhdX1v-6G6E Spotify: https://open.spotify.com/show/7F0JHBoB5SWvAi12WNmR2e Apple Podcasts: https://podcasts.apple.com/us/podcast/vyzer-weekly/id1859061480 Register for the next live call: https://go.vyzer.co/vyzerweeklycalls Vyzer Weekly Calls are weekly, live conversations designed to help investors think more clearly about risk, private investing, and long-term decision-making.

  ListenShow Notes
• 

  Episode #25

  Why You Can't Actually Invest in a Data Center (And the One Way You Can)

  Sep 10, 202655 minS1

  Everyone is buying data centers. Someone has to get them approved, and that turns out to be the part nobody can do. Most investors hearing about the AI build out are being sold a story they cannot actually buy into. A turnkey data center runs $10 to $15 million per megawatt. A 50 megawatt site is half a billion dollars before a single server goes in. The building itself is institutional capital only, full stop. In this episode of Vyzer Weekly Calls, Litan Yahav and Mike Arndorfer are joined by Jamie Earp, who has spent close to two decades getting contentious digital infrastructure approved across hundreds of US jurisdictions. Cell towers first, then fiber, now data centers. The conversation is about where the actual constraint sits, and whether there is any door in for someone writing a normal check. In this conversation, we discuss: Why a data center is an infrastructure play and not a technology play, and why that changes how you underwrite it What these things really cost: $2 to $3 million a megawatt for a powered shell, $10 to $15 million fully built out The one layer a non-institutional investor can access, where entitled and powered sites trade at roughly $150,000 to $750,000 a megawatt Why this boom is not the tower bubble or the fiber bubble: the demand is already here, and only about 10% of announced compute capacity has actually come online How the politics flipped in six months, why Texas hit the brakes, and what New York's 50 megawatt moratorium does and does not block The water and power claims sorted out: closed loop cooling, how usage compares to a golf course, and why electricity prices move in deregulated markets specifically Why the grid stays the holy grail even for sites generating their own power, and where nuclear and natural gas realistically fit Mike's pushback on the one accessible deal shape: a preferred return with 90% of the upside going to the sponsor puts you first in line for the loss and last for the gain What happens to returns when the supply gap closes, and Jamie's estimate of how long that takes This is not a presentation or a pitch. It is a live, open conversation about how individual investors should think about an asset class that is mostly being marketed to people who cannot buy it. About Jamie Earp Jamie Earp has worked in digital infrastructure for close to 20 years. He co-founded and served as President of Branch Communications, which built a portfolio of more than 900 wireless assets across 38 states and Puerto Rico, and co-founded Ubiquity, an owner and operator of fiber networks and edge data centers. His background is in getting contentious infrastructure sited and approved: rezonings, special use hearings, planning boards, and neighborhood opposition. Listen and subscribe YouTube: https://www.youtube.com/playlist?list=PLVH9Pz5-HyDBtJSrgG6tbZhhdX1v-6G6E Spotify: https://open.spotify.com/show/7F0JHBoB5SWvAi12WNmR2e Apple Podcasts: https://podcasts.apple.com/us/podcast/vyzer-weekly/id1859061480 Register for the next live call: https://go.vyzer.co/vyzerweeklycalls Jamie offered to take questions one on one. He is at Jamie@DigitalVenturesGP.com Vyzer Weekly Calls are weekly, live conversations designed to help investors think more clearly about risk, private investing, and long-term decision-making.

  ListenShow Notes
• 

  Episode #24

  17 Ways a Real Estate Syndication Can Break

  Aug 27, 202657 minS1

  Most LPs don't discover the risk they accepted until it has already cost them money. By then it isn't a risk anymore. It's a stress point, and the deal is usually past the stage where anything can be done about it. The uncomfortable part is that the warning signs were sitting in the pitch deck the whole time. In this episode of Vyzer Weekly Calls, Litan Yahav and Mike Arndorfer are joined by Christine, an LP who has been investing in syndicated real estate since 2018 and spent the last year building a system for the thing she felt she had gotten wrong: understanding risk before committing capital. She calls it the Risk Radar. This call is the community stress-testing it in real time. In this conversation, we discuss: - Why the risk you took only becomes visible once it has become a stress point - The three rings of the Risk Radar: what is fixed at closing, what the market drives, and what the sponsor controls - Why every single variable should be able to kill a deal on its own, and why you should stop rather than finish the analysis - The difference between a deal that implodes and a deal that is dead to you, and how layers of rescue capital wipe out common equity on a "successful" exit - Whether low risk and high reward can actually coexist, and a sharp disagreement over what standard risk and return theory gets wrong - Where the framework breaks down on blind pool funds, and why it gets more useful the later you come into one - How far you can trust AI to populate market data, and the 70/30 split between what it gets you and where you still have to do the work - Why a sponsor's refusal to share a number is itself a maximum-risk data point This is not a presentation or a pitch. It's a live, open conversation focused on how passive investors can see risk clearly before they commit capital, not after. About Christine Christine has invested as an LP in syndicated real estate since 2018 and created the Risk Radar, a free framework for mapping deal risk across market-driven and sponsor-driven variables. The blank templates, user manual, asset-class variants, and AI guide are all available on her site. https://www.netzeroisawin.com/s/the-risk-radar Listen and subscribe YouTube: https://www.youtube.com/playlist?list=PLVH9Pz5-HyDBtJSrgG6tbZhhdX1v-6G6E Spotify: https://open.spotify.com/show/7F0JHBoB5SWvAi12WNmR2e Apple Podcasts: https://podcasts.apple.com/us/podcast/vyzer-weekly/id1859061480 Register for the next live call: https://go.vyzer.co/vyzerweeklycalls Vyzer Weekly Calls are weekly, live conversations designed to help investors think more clearly about risk, private investing, and long-term decision-making.

  ListenShow Notes
• 

  Episode #23

  Jeremy Roll: What Diversification Actually Means for LPs

  Jul 9, 202659 minS1

  Jeremy Roll has been a full-time LP for 24+ years and has lived off his private-market cash flow since 2007. He joins Litan Yahav and Mike to unpack what diversification really means once you leave stocks and bonds behind. The big idea: spreading money across five deals with the same operator isn't diversification. Real risk-spreading happens across three axes at once, asset class, geography, and operator. In this episode: Why capital events (refis, sales) get reinvested, never treated as spendable cash flow The trap in fully-amortized deals like ATMs and equipment leasing Funds vs. single-asset deals, and what the mix reveals about where we are in the cycle Reading blind-pool fund docs before you wire Position limits and why proper private diversification takes 5-10 years How Jeremy vets operators, and where gold and Bitcoin fit An educational conversation between LPs. Not financial advice, and nothing is being sold.

  ListenShow Notes
• 

  Episode #23

  Jeremy Roll: What Diversification Actually Means for LPs

  Jul 9, 202659 minS1

  <p>Jeremy Roll has been a full-time LP for 24+ years and has lived off his private-market cash flow since 2007. He joins Litan Yahav and Mike to unpack what diversification really means once you leave stocks and bonds behind.</p><p><br></p><p>The big idea: spreading money across five deals with the same operator isn't diversification. Real risk-spreading happens across three axes at once, asset class, geography, and operator.</p><p><br></p><p>In this episode:</p><p><br></p><p>Why capital events (refis, sales) get reinvested, never treated as spendable cash flow</p><p>The trap...

  ListenShow Notes

Recent guests on Vyzer Weekly. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.